Executive Salary
avg.$219,753
ascendis pharma
Life Science/Pharmaceutical Industry
Hellerup, Denmark
Description
Ascendis Pharma, founded in 2006 and headquartered in Hellerup, Denmark, is a publicly traded biotechnology company focused on developing transformative therapies in endocrinology rare diseases and oncology. The company's innovative TransCon technology platform enables the development of new treatments aimed at improving safety, efficacy, tolerability, and convenience for patients. With approximately 1,017 employees, Ascendis Pharma serves both B2B and B2C markets and reported a total revenue of $393.4 million. The company operates globally but maintains a strong presence in the United States, where it targets healthcare providers and patients seeking advanced therapeutic options for complex medical conditions.
Experteer Insights
Experteer Briefing
Company Trajectory
Ascendis Pharma, founded in 2006 and headquartered in Hellerup, Denmark, was established to develop improved, patentable versions of high-value drugs utilizing its proprietary TransCon technology. The company initially concentrated on enhancing established medications for greater efficacy and safety. Over its trajectory, Ascendis Pharma has evolved from its original focus, making strategic advancements in its core technology and expanding into additional therapeutic areas such as rare endocrinology diseases and oncology. Moving forward, the company continues to leverage its platform to address unmet needs within highly specialized medical markets.
Financial Setup
Ascendis Pharma is a publicly traded company serving both B2B and B2C markets. With an employee base of approximately 1,020, the company draws from global talent to support its research and commercial operations. The organization’s financial structure has supported significant growth and product development, enabling ongoing investment in its proprietary platform and portfolio expansion. The current business model is centered on developing therapies that offer best-in-class potential for safety, efficacy, tolerability, and convenience.
Development & Outlook
Specializing in therapies for rare endocrine diseases and oncology, Ascendis Pharma relies on its patented TransCon technology platform as the cornerstone for innovation. Its product portfolio features SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for adult hypoparathyroidism. A robust pipeline includes investigational treatments for achondroplasia and several solid tumors. The company continues to focus on research and development as well as the advancement of its proprietary technologies, positioning itself for ongoing growth and leadership in addressing complex and underserved patient needs.
Vacancies
Associate Director, Program Safety Lead - Job ID: 1908
ascendis pharma
Princeton, NJ - USA
Associate Director, Program Safety Lead - Job ID: 1908
ascendis pharma
Princeton, NJ - USA
Director, Clinical & Medical Strategic Planning & Management - Job ID: 1911
ascendis pharma
Palo Alto, CA - USA
Director, Clinical & Medical Strategic Planning & Management - Job ID: 1911
ascendis pharma
Princeton, CA - USA
Sr. Manager, Global Medical Information - Job ID: 1918
ascendis pharma
Palo Alto, CA - USA